Publicaciones en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (16)

2024

  1. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis

    European Journal of Cancer, Vol. 207

2023

  1. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 21, pp. 3663-3669

  2. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database

    Cancers, Vol. 15, Núm. 16

2021

  1. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis

    Therapeutic Advances in Medical Oncology, Vol. 13

2019

  1. Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer

    JAMA network open, Vol. 2, Núm. 9, pp. e1911750

  2. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

    Critical Reviews in Oncology/Hematology, Vol. 134, pp. 39-45

2017

  1. Clinical calculator for Early mortality in Metastatic colorectal cancer: An analysis of Patients from 28 clinical trials in the aide et recherche en cancérologie digestive database

    Journal of Clinical Oncology, Vol. 35, Núm. 17, pp. 1929-1937

2016

  1. Body mass index is prognostic in metastatic colorectal cancer: Pooled analysis of patients from first-line clinical trials in the ARCAD database

    Journal of Clinical Oncology, Vol. 34, Núm. 2, pp. 144-150

  2. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

    The Lancet Oncology, Vol. 17, Núm. 12, pp. 1709-1719

2015

  1. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: Findings from the analysis and research in cancers of the digestive system database

    Journal of Clinical Oncology, Vol. 33, Núm. 1, pp. 22-28

2014

  1. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data

    The Lancet Oncology, Vol. 15, Núm. 4, pp. 406-414

2011

  1. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results

    British Journal of Cancer, Vol. 105, Núm. 1, pp. 58-64

2008

  1. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study

    Journal of Clinical Oncology, Vol. 26, Núm. 12, pp. 2013-2019

2007

  1. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006

    Annals of Oncology

2006

  1. The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005

    Annals of Oncology

2002

  1. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001)

    European Journal of Cancer, Vol. 38, Núm. 11, pp. 1429-1436